Drug intelligence / Profile preview

CNC-101

Development stage: Preclinical
Lead developer: CNcure
Modality: Small Molecules
Administration: Intravenous

Overview

CNC-101 is an early-stage therapeutic candidate being developed by CNcure for the treatment of solid tumors. Discovered through the company's proprietary AICureX AI-driven drug discovery platform, the program is currently in the hit-to-lead optimization phase. The AICureX platform is designed to accelerate the identification of novel compounds with high therapeutic potential by utilizing artificial intelligence to optimize drug candidates. Specific molecular targets for CNC-101 have not yet been publicly disclosed, but the asset is part of a pipeline focused on addressing unmet needs in oncology.

Beyond the preview

Go deeper on CNC-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNC-101.

Explore the full profile